Ginkgo Bioworks Holdings Inc
A Synthetic Biology company that uses advanced technologies to design, build and test biological systems.
Stock Performance Snapshot
Analyst Rating
Analysts suggest selling Ginkgo Bioworks' stock as its target price is significantly higher than its current price.
Financial Health
Ginkgo Bioworks is generating strong revenue and profit margins, showing solid financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DNA
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform potential
Ginkgo’s cell‑programming platform could unlock recurring services and licensing revenue as customers scale, though commercial outcomes and timing can vary.
Partnership momentum
Collaborations and agreements can accelerate revenue and validation, but returns depend on execution and may take time to materialise.
Science and regulation
Scientific progress and regulatory approvals shape long‑term value; investors should expect developmental and policy uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
